Claims for Patent: 9,504,645

Summary for Patent: 9,504,645

Title:	Pharmaceutical formulations for treating ocular conditions
Abstract:	Described herein are pharmaceutical formulations for treating ocular conditions.
Inventor(s):	Ackermann, Jr.; Douglas Michael (San Francisco, CA), Loudin; James (Houston, TX), Mandell; Kenneth J. (Arlington, MA)
Assignee:	OYSTER POINT PHARMA, INC. (South San Francisco, CA)
Application Number:	14/887,259
Patent Claims:	1. A pharmaceutical formulation for local administration into the nasal cavity of an individual comprising a non-systemically bio available dose between 5 micrograms and 50 micrograms of varenicline per dose formulated (a) for nasal administration and (b) to prevent desensitization. 2. The pharmaceutical formulation of claim 1, wherein varenicline is formulated in a dosage amount that does not result in undesired psychoactive side effects. 3. The pharmaceutical formulation of claim 1, wherein varenicline is formulated in a dosage amount that does not result in undesired systemic side effects. 4. The pharmaceutical formulation of claim 1, further comprising one or more substances selected from protein kinase C (PKC) or factors that upregulate or up-modulate PKC, cAMP-dependent protein kinase (PKA) or factors that upregulate or up-modulate PKA, and calcineurin inhibitors. 5. The pharmaceutical formulation of claim 4, wherein the calcineurin inhibitor is selected from cyclosporine, pimecrolimus, and tacrolimus. 6. The pharmaceutical formulation of claim 1, wherein varenicline selectively binds to at least one of the peripheral nicotinic acetylcholine receptor subtypes selected from alpha3beta4, alpha4beta2, and alpha7. 7. The pharmaceutical formulation of claim 1, wherein the pharmaceutical formulation comprises about 1 mg/mL of varenicline. 8. The pharmaceutical formulation of claim 1, wherein the pharmaceutical formulation comprises about 0.5 mg/mL of varenicline. 9. The pharmaceutical formulation of claim 1, wherein the formulation is administered at least once daily. 10. The pharmaceutical formulation of claim 1, wherein the formulation is administered at least twice daily. 11. The pharmaceutical formulation of claim 1, wherein the formulation is administered at least once weekly. 12. The pharmaceutical formulation of claim 1, wherein the formulation is administered into the nasal cavity as a liquid, suspension, aerosol, gel, ointment, dry powder, cream, paste, lotion, or balm. 13. The pharmaceutical formulation of claim 1, wherein the formulation is administered into the nasal cavity by a syringe, dropper, bottle nebulizer, atomization pump, inhaler, powder spray device, vaporizer, patch, medicated stick, pipette, or jet of liquid.